Betahistine in vestibular vertigo and VIRTUOSO post-marketing observational program

The article tells about the specifics of vestibular vertigo and clinical manifestations of diseases commonly associated with dizziness. The efficacy, safety and good tolerability of betahistine hydrochloride (Betaserc) in various diseases characterized by vestibular vertigo is demonstrated. The desi...

Full description

Bibliographic Details
Main Authors: SV Morozova, VA Parfenov, MV Zamergrad
Format: Article
Language:Russian
Published: Remedium Group LLC 2014-12-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/597
id doaj-4a8a467328f7489da18cf70e2434a43e
record_format Article
spelling doaj-4a8a467328f7489da18cf70e2434a43e2021-07-28T13:29:17ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902014-12-0107343810.21518/2079-701X-2014-7-34-38597Betahistine in vestibular vertigo and VIRTUOSO post-marketing observational programSV Morozova0VA Parfenov1MV Zamergrad2Clinic and Department of ENT Diseases, First Moscow State Medical University named after I.M.SechenovClinic and Department of Nervous Diseases and NeurosurgeryClinic and Department of Nervous Diseases and NeurosurgeryThe article tells about the specifics of vestibular vertigo and clinical manifestations of diseases commonly associated with dizziness. The efficacy, safety and good tolerability of betahistine hydrochloride (Betaserc) in various diseases characterized by vestibular vertigo is demonstrated. The design of the VIRTUOSO observational program to evaluate Betaserc effects in patients with vertigo in routine clinical practice, is described. The authors note that the study results will help to further assess the efficacy and safety of Betaserc and determine in which diseases the drug is most often used in Russia and Ukraine.https://www.med-sovet.pro/jour/article/view/597вестибулярное головокружениебетагистина гидрохлоридбетасеркисследование virtuosovestibular vertigobetahistine hydrochloridebetasercvirtuoso
collection DOAJ
language Russian
format Article
sources DOAJ
author SV Morozova
VA Parfenov
MV Zamergrad
spellingShingle SV Morozova
VA Parfenov
MV Zamergrad
Betahistine in vestibular vertigo and VIRTUOSO post-marketing observational program
Медицинский совет
вестибулярное головокружение
бетагистина гидрохлорид
бетасерк
исследование virtuoso
vestibular vertigo
betahistine hydrochloride
betaserc
virtuoso
author_facet SV Morozova
VA Parfenov
MV Zamergrad
author_sort SV Morozova
title Betahistine in vestibular vertigo and VIRTUOSO post-marketing observational program
title_short Betahistine in vestibular vertigo and VIRTUOSO post-marketing observational program
title_full Betahistine in vestibular vertigo and VIRTUOSO post-marketing observational program
title_fullStr Betahistine in vestibular vertigo and VIRTUOSO post-marketing observational program
title_full_unstemmed Betahistine in vestibular vertigo and VIRTUOSO post-marketing observational program
title_sort betahistine in vestibular vertigo and virtuoso post-marketing observational program
publisher Remedium Group LLC
series Медицинский совет
issn 2079-701X
2658-5790
publishDate 2014-12-01
description The article tells about the specifics of vestibular vertigo and clinical manifestations of diseases commonly associated with dizziness. The efficacy, safety and good tolerability of betahistine hydrochloride (Betaserc) in various diseases characterized by vestibular vertigo is demonstrated. The design of the VIRTUOSO observational program to evaluate Betaserc effects in patients with vertigo in routine clinical practice, is described. The authors note that the study results will help to further assess the efficacy and safety of Betaserc and determine in which diseases the drug is most often used in Russia and Ukraine.
topic вестибулярное головокружение
бетагистина гидрохлорид
бетасерк
исследование virtuoso
vestibular vertigo
betahistine hydrochloride
betaserc
virtuoso
url https://www.med-sovet.pro/jour/article/view/597
work_keys_str_mv AT svmorozova betahistineinvestibularvertigoandvirtuosopostmarketingobservationalprogram
AT vaparfenov betahistineinvestibularvertigoandvirtuosopostmarketingobservationalprogram
AT mvzamergrad betahistineinvestibularvertigoandvirtuosopostmarketingobservationalprogram
_version_ 1721274585586860032